|
1
|
Zhu T, Li M, Zhu M, Liu X, Huang K, Li W, Wang SX, Yin Y, Li P. Epigallocatechin-3-gallate alleviates type 2 diabetes mellitus via β-cell function improvement and insulin resistance reduction. Iran J Basic Med Sci 2022; 25:483-488. [PMID: 35656076 PMCID: PMC9150804 DOI: 10.22038/ijbms.2022.58591.13016] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 06/26/2021] [Accepted: 04/18/2022] [Indexed: 12/03/2022]
Abstract
OBJECTIVES Epigallocatechin-3-gallate (EGCG) has a good therapeutic effect on type 2 diabetes mellitus (T2DM). This work was designed to explore EGCG's effectiveness in insulin resistance (IR) and pancreas islet β-cell function in a rat model of T2DM. MATERIALS AND METHODS Eight-week-old male Sprague Dawley rats were randomly divided into 6 groups, including the Control (normal diet), Diabetes (high-sucrose high-fat [HSHF] diet combined with tail vein injection of streptozotocin [STZ] for T2DM induction) and Treatment Diabetic rats which were treated with metformin [500 mg/kg/d] or EGCG [25, 50 or 100 mg/kg/d] intragastric administration for 10 weeks. With the exception of control animals, the other groups were fed the HSHF diet. EGCG's effects on IR and insulin secretion were assessed by measuring body weights, and fasting blood glucose (FBG), postprandial blood glucose (PBG) and insulin levels. The morphological and molecular changes of pancreas islet β-cells were examined by hematoxylin-eosin (H&E) staining, transmission electron microscopy (TEM) and immunofluorescence. RESULTS Rats fed the HSHF diet combined with STZ treatment had increased body weights and blood glucose amounts, accompanied by IR and impaired β-cell function, induced T2DM, and EGCG dose-dependently restored the above indicators. Additionally, EGCG upregulated the pancreatic transcription factors pancreatic duodenal homeobox protein-1 (PDX-1) and musculoaponeurotic fibrosarcoma oncogene homolog A (MafA). CONCLUSION These results suggest that EGCG reduces blood glucose amounts, and improve IR and islet β-cell disorder in T2DM.
Collapse
Affiliation(s)
- Tiantian Zhu
- College of Pharmacy, Xinxiang Medical University, Xinxiang, China,Henan International Joint Laboratory of Cardiovascular Remodeling and Drug Intervention, Xinxiang, China,Xinxiang Key Laboratory of Vascular Remodeling Intervention and Molecular Targeted Therapy Drug Development, Xinxiang, China, These authors contributed equally to this work
| | - Minghui Li
- College of Pharmacy, Xinxiang Medical University, Xinxiang, China,Henan International Joint Laboratory of Cardiovascular Remodeling and Drug Intervention, Xinxiang, China,Xinxiang Key Laboratory of Vascular Remodeling Intervention and Molecular Targeted Therapy Drug Development, Xinxiang, China, These authors contributed equally to this work
| | - Moli Zhu
- College of Pharmacy, Xinxiang Medical University, Xinxiang, China,Henan International Joint Laboratory of Cardiovascular Remodeling and Drug Intervention, Xinxiang, China,Xinxiang Key Laboratory of Vascular Remodeling Intervention and Molecular Targeted Therapy Drug Development, Xinxiang, China
| | - Xu Liu
- College of Pharmacy, Xinxiang Medical University, Xinxiang, China,Henan International Joint Laboratory of Cardiovascular Remodeling and Drug Intervention, Xinxiang, China,Xinxiang Key Laboratory of Vascular Remodeling Intervention and Molecular Targeted Therapy Drug Development, Xinxiang, China
| | - Keke Huang
- College of Pharmacy, Xinxiang Medical University, Xinxiang, China,Henan International Joint Laboratory of Cardiovascular Remodeling and Drug Intervention, Xinxiang, China,Xinxiang Key Laboratory of Vascular Remodeling Intervention and Molecular Targeted Therapy Drug Development, Xinxiang, China
| | - Wenru Li
- College of Pharmacy, Xinxiang Medical University, Xinxiang, China,Henan International Joint Laboratory of Cardiovascular Remodeling and Drug Intervention, Xinxiang, China,Xinxiang Key Laboratory of Vascular Remodeling Intervention and Molecular Targeted Therapy Drug Development, Xinxiang, China
| | - Shuang-Xi Wang
- College of Pharmacy, Xinxiang Medical University, Xinxiang, China,Henan International Joint Laboratory of Cardiovascular Remodeling and Drug Intervention, Xinxiang, China,Xinxiang Key Laboratory of Vascular Remodeling Intervention and Molecular Targeted Therapy Drug Development, Xinxiang, China, These authors contributed equally to this work
| | - Yaling Yin
- Henan International Joint Laboratory of Cardiovascular Remodeling and Drug Intervention, Xinxiang, China,Xinxiang Key Laboratory of Vascular Remodeling Intervention and Molecular Targeted Therapy Drug Development, Xinxiang, China,School of Basic Medical Sciences, Xinxiang Medical University, Xinxiang, China,Corresponding authors: Yaling Yin. School of Basic Medical Sciences, Xinxiang Medical University, No. 601 Jin-sui Road, Xinxiang 453003, Henan, China. Tel: 86-0373-3029918; Fax: 86-0373-3029918; ; Peng Li. College of Pharmacy, Xinxiang Medical University, No. 601 Jin-sui Road, Xinxiang 453003, Henan, China. Tel: +86 18530238975; Fax: +86 2039358270;
| | - Peng Li
- College of Pharmacy, Xinxiang Medical University, Xinxiang, China,Henan International Joint Laboratory of Cardiovascular Remodeling and Drug Intervention, Xinxiang, China,Xinxiang Key Laboratory of Vascular Remodeling Intervention and Molecular Targeted Therapy Drug Development, Xinxiang, China,Corresponding authors: Yaling Yin. School of Basic Medical Sciences, Xinxiang Medical University, No. 601 Jin-sui Road, Xinxiang 453003, Henan, China. Tel: 86-0373-3029918; Fax: 86-0373-3029918; ; Peng Li. College of Pharmacy, Xinxiang Medical University, No. 601 Jin-sui Road, Xinxiang 453003, Henan, China. Tel: +86 18530238975; Fax: +86 2039358270;
| |
Collapse
|